Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-05-09
2006-05-09
Lewis, Patrick (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S054000, C514S930000, C536S018700, C536S055200, C536S123100
Reexamination Certificate
active
07041657
ABSTRACT:
The present invention relates to compositions comprising semi-crystalline β-1-4-N-acetylglucosamine polymers (p-GlcNac) and methods utilizing such polymers modulation of vascular structure and/or function. The compositions and methods disclosed are useful for stimulating, in a p-GlcNac concentration-dependent manner, endothelin-1 release, vasoconstriction, and/or reduction in blood flow out of a breached vessel, as well as for contributing to or effecting cessation of bleeding. The methods of the present invention comprise topical administration of materials comprising semi-crystalline p-GlcNac polymers that are free of proteins, and substantially free of single amino acids as well as other organic and inorganic contaminants, and whose constituent monosaccharide sugars are attached in a β-1-4 conformation.
REFERENCES:
patent: 5219749 (1993-06-01), Bouriotis et al.
patent: 5622834 (1997-04-01), Vournakis et al.
patent: 5623064 (1997-04-01), Vournakis et al.
patent: 5624679 (1997-04-01), Vournakis et al.
patent: 5635493 (1997-06-01), Vournakis et al.
patent: 5686115 (1997-11-01), Vournakis et al.
patent: 5846952 (1998-12-01), Vournakis et al.
patent: 5858350 (1999-01-01), Vournakis et al.
patent: 6063911 (2000-05-01), Vournakis et al.
Barton et al. “Endothelin antagonists for hypertension and renal diseases” Curr. Opin. Nephrol. Hypertens. (1999), vol. 8, pp. 549-556.
Pearson “Normal endothelial cell function” Lupus (2000), vol. 9, pp. 183-188.
Webster's II: New Riverside university Dictionary, The Riverside Publishing Company (1994), p. 155.
Alsip et al., 1996, “A new technique for studying the uterine microvasculature in the rat”, Am. J. Obstet. Gynecol. 175:388-395.
Austin and Sennett, 1986, “Dry chitosan salts and complexes of aliphatic carboxylic acids”, in:Chitin in Nature and Technology, Muzzarelli et al., eds., Plenum Press, New York, pp. 279-286.
Barton and Luscher, 1999, “Endothelin antagonists for hypertension and renal disease”, Curr. Opin. Nephrol. Hypertens. 8:549-556.
Becker et al., 2000, “Endothelial function and hemostasis”, Z. Kardiol. 89:160-167.
Brooks et al., 1991, “Effect of nifedipine on cyclosporine A-induced nephrotoxicity, urinary endothelin excretion and renal endothelin receptor number”. Eur. J. Pharmacol. 194:115-117.
Caron et al., 1998, “Proposition of a technique to assess the vasoactive effects of hemoglobin-based oxygen carrying solutions in vivo: preliminary results in the rabbit aorta”, Artif. Cells Blood Substit. Immobil. Biotechnol. 26:293-308.
Davidson et al., 2000, “Experimental study of a novel fibrin sealant for achieving haemostasis following partial hepatectomy”, Br. J. Surg. 87:790-795.
Davis and Preston, 1981, “A simple modified carbodiimide method for conjugation of small-molecular-weight compounds to immunoglobulin G with minimal protein crosslinking”, Anal. Biochem. 116:402-407.
Domard, 1986, “Circular dichroism study onN-acetylglucosamine oligomers”, Int. J. Biol. Macromol. 8:243-246.
Dupuis, 2000, “Endothelin receptor antagonists and their developing role in cardiovascular therapeutics”, Can. J. Cardiol. 16:903-910.
Emerson et al., 1999, “Endogenous nitric oxide acts as a natural antithrombotic agentin vivoby inhibiting platelet aggregation in the pulmonary vasculature”, Thromb. Haemost. 81:961-966.
Goldie, 1999, “Endothelins in health and disease: an overview”, Clin. Exp. Pharmacol. Physiol. 26:145-148.
Guo et al., 1994, “Endothelial preserving actions of a nitric oxide donor in carotid arterial intimal injury”, Methods Find. Exp. Clin. Pharmacol. 15:347-354.
Hirano, 1989, “Production and application of chitin and chitosan in Japan”, in:Chitin and Chitosan, Skjak-Brack et al., eds., Elsevier Science Publishing Co., pp. 37-43.
Hirano et al., 1981, “SEM ultrastructure studies ofN-acyl- andN-benzylidene-chitosan and chitosan membranes”, J. Biomed. Mater. Res. 15:903-911.
Hirano et al., 1976, “SelectiveN-acylation of chitosan”, Carbohydrate Res. 47:315-320.
Hocher et al., 1997, “The paracrine endothelin system: pathophysiology and implications in clinical medicine”, Eur. J. Clin. Chem. Clin. Biochem. 35:175-189.
Inoue et al., 1989, “The human endothelin family: three structurally and pharmacologically distinct isopepides predicted by three separate genes”, Proc. Natl. Acad. Sci. USA 86:2863-2867.
Ishida et al., 1989, “Differential activities of two distinct endothelin family peptides on ileum and coronary artery”, FEBS Lett. 247:337-340.
Kashiwabara et al., 1989, “Putative precursosrs of endothelin have less vasoconstrictor activity in vitro but a potent pressor effect in vivo”, FEBS Lett. 247:73-76.
Kim and Greenburg, 2000, “Pharmacodynamic characterization of hemoglobin-induced vasoactivity in isolated rat thoracic aorta”, J. Lab. Clin. Med. 135:180-187.
Komai et al., 1986, “Biomedical evaluation of acylated chitins as coating materials”, in:Chitin in Nature and Technology, Muzzarelli et al., eds., Plenum Press, New York, pp. 497-506.
Kurita et al., 1990, “Preparations of soluble chitin derivatives and the modifications to branched chitins”, Polymer Prep. 31:624-625.
Kurita and Inoue, 1989, “Preparation of indo-chitins and graft copolymerization onto the derivatives”, in:Chitin and Chitosan, Skjak-Brack et al., eds., Elsevier Science Publishing Co., p. 365.
Lüscher and Wenzel, 1995, “Endothelin and endothelin antagonists: pharmacology and clinical implications”, Agents Actions Suppl. 45:237-253.
Maresh et al., 1989, “Hydroxypropylation of chitosan”, in:Chitin and Chitosan, Skjak-Brack et al., eds., Elsevier Science Publishing Co., pp. 389-395.
Mireles et al., 1992, “ Complex formation of chitosan and naturally occurring polyanion”, in:Advances in Chitin and Chitosan, Brine et al., eds., Elsevier Publishers, Ltd. , pp. 506-515.
Nishi et al., 1986, “Preparation and characterization of phosphorylated chitin and chitosan”, in:Chitin in Nature and Technology, Muzzarelli et al., eds., Plenum Press, New York, pp. 297-299.
Noguchi et al., 1969, “Chitosan epichlorohydrin anion exchange resin with primary amine as absorption site”, Kogyo Kagaku Zasshi 72:796-799 (in Japanese with English abstract).
Ortega Mateo and de Artinano, 1997, “Highlights on endothelins: a review”, Pharmacological Res. 36:339-351.
Pasricha et al., 1999, “Endoscopic cryotherapy: experimental results and first clinical use”, Gastrointest. Endosc. 49:627-631.
Pearson, 2000, “Normal endothelial cell function”, Lupus 9:183-188.
Rosendorff, 1996, “Endothelin, vascular hypertrophy, and hypertension”, Cardiovasc. Drugs Ther. 10:795-802.
Saida et al., 1989, “A novel peptide, vasoactive intestinal contractor, of a new (endothelin) peptide family. Molecular cloning, expression, and biological activity”, J. Biol. Chem. 264:14613-14616.
Salamonsen et al., 1999, “Current concepts of the mechanisms of menstruation”, Ballière's Best Pract. Res. Clinical Obstetrics and Gynaecology 13:161-179.
Salamonsen et al., 1999, “Endometrial endothelin: regulator of uterine bleeeding and endometrial repair”, Clin. Exp. Pharmacol. Physiol. 26:154-157.
Schiffrin et al., 1995, “Antihypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats”, Br. J. Pharmacol. 115:1377-1381.
Schini-Kerth, 1999, “Vascular biosynthesis of nitric oxide: effect on hemostasis and fibrinolysis.”, Transfus. Clin. Biol. 6:355-363.
Schorigin and Halt, 1934, “Über die nitriering von chitin”, Chem. Ber. 67:1712-1714 (in German).
Schweiger, 1972, “Polysaccharide sulfates. I. Cellulose sul
Finkielsztein Sergio
Vournakis John N
Jones Day
Lewis Patrick
Marine Polymer Technologies Inc.
LandOfFree
Compositions and methods for modulation of vascular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for modulation of vascular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for modulation of vascular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3646956